People with a history of cognitively stimulating occupations during their 30s, 40s, 50s, and 60s had a lower risk of mild cognitive impairment and dementia after age 70.
Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
With funding from the Ultra-rare Gene-based Therapy Network, scientists at Columbia and the n-Lorem Foundation will create tailor-made gene-based therapies for people with rare forms of ALS.
Many researchers believe that the neurodegenerative disorder gets started in the gut. Columbia research now suggests that an autoimmune reaction may be driving those early events.
Columbia researchers have identified brain circuits that, when injured, make conscious patients with acute brain injury appear unresponsive, a phenomenon known as hidden consciousness.
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
A study of professionals in the National Hockey League found that players who frequently engaged in fighting on the ice died a decade earlier than less pugilistic players.
Age-related memory loss is caused, in part, by lack of flavanols—nutrients found in certain fruits and vegetables—according to a large study in older adults.